Published in Hepatology on October 01, 2002
Noradrenalin vs Terlipressin in Hepatorenal Syndrome | NCT00370253
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut (2007) 4.51
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology (2008) 2.69
Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol (2012) 1.47
Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care (2012) 1.30
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci (2007) 1.18
Acute renal dysfunction in liver diseases. World J Gastroenterol (2007) 1.15
Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci (2007) 1.13
Current management of the complications of portal hypertension: variceal bleeding and ascites. CMAJ (2006) 1.10
Outcomes of patients with cirrhosis undergoing non-hepatic surgery: risk assessment and management. World J Gastroenterol (2007) 1.07
Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol (2011) 0.99
Innate immune dysfunction in acute and chronic liver disease. Wien Klin Wochenschr (2009) 0.96
Clinical use of albumin in hepatology. Blood Transfus (2009) 0.96
Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol (2012) 0.94
Albumin for end-stage liver disease. Korean J Intern Med (2012) 0.93
Hepatorenal syndrome. World J Gastroenterol (2012) 0.93
Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr (2013) 0.93
Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol (2008) 0.93
Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci (2006) 0.92
Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol (2011) 0.92
Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J Hepatol (2013) 0.91
Management of portal hypertension. Postgrad Med J (2004) 0.90
Human albumin in the management of complications of liver cirrhosis. Crit Care (2012) 0.86
Improving survival in decompensated cirrhosis. Int J Hepatol (2012) 0.86
Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis (2011) 0.85
Alcoholic Hepatitis. Curr Treat Options Gastroenterol (2004) 0.84
Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol (2014) 0.82
Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress. World J Hepatol (2015) 0.82
Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management. World J Gastroenterol (2015) 0.82
Hepatorenal syndrome. Clin Biochem Rev (2007) 0.80
Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int (2008) 0.79
Clinical use of albumin. Blood Transfus (2013) 0.79
Hyponatremia and Hepatorenal Syndrome. Gastroenterol Hepatol (N Y) (2015) 0.79
The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. J Gastroenterol (2011) 0.79
A case of peripheral gangrene and osteomyelitis secondary to terlipressin therapy in advanced liver disease. Clin Mol Hepatol (2013) 0.78
Hepatorenal syndrome: outcome of response to therapy and predictors of survival. Gastroenterol Res Pract (2015) 0.78
Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study. Dig Dis Sci (2013) 0.78
Optimal management of hepatorenal syndrome in patients with cirrhosis. Hepat Med (2010) 0.78
Terlipressin and albumin for HRS: an advance in therapy? Gastroenterology (2003) 0.77
Haemodynamic effects of plasma-expansion with hyperoncotic albumin in cirrhotic patients with renal failure: a prospective interventional study. BMC Gastroenterol (2008) 0.77
Treatment and management of ascites and hepatorenal syndrome: an update. Therap Adv Gastroenterol (2015) 0.77
A Treat-to-Target Concept to Guide the Medical Management of Hepatorenal Syndrome. Dig Dis Sci (2014) 0.77
Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. World J Gastroenterol (2010) 0.76
Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion. World J Hepatol (2016) 0.76
Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus. World J Hepatol (2016) 0.76
Contribution of diuretic therapy with human serum albumin to the management of ascites in patients with advanced liver cirrhosis: A prospective cohort study. Mol Clin Oncol (2014) 0.76
Terlipressin-induced ischemic skin necrosis: a rare association. Am J Case Rep (2014) 0.75
Hepatorenal syndrome. World J Gastroenterol (2007) 0.75
Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure. Nephron (2015) 0.75
Acute Kidney Injury in Patients with Cirrhosis. J Clin Transl Hepatol (2015) 0.75
Terlipressin and albumin for the hepatorenal syndrome. Hepatology (2003) 0.75
Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response? Springerplus (2015) 0.75
AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. Blood Transfus (2016) 0.75
Management of cirrhotic ascites. Ther Adv Chronic Dis (2015) 0.75
Renal dysfunction in patients with chronic liver disease. Electrolyte Blood Press (2009) 0.75
Renal dysfunction in cirrhosis: diagnosis, treatment and prevention. MedGenMed (2004) 0.75
The efficacy and safety profile of albumin administration for patients with cirrhosis at high risk of hepatorenal syndrome is dose dependent. Gastroenterol Rep (Oxf) (2015) 0.75
5 Human Albumin. Transfus Med Hemother (2009) 0.75
Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis. PLoS One (2015) 0.75
Renal failure in cirrhosis: Emerging concepts. World J Hepatol (2015) 0.75
Role of albumin in cirrhosis: from a hospitalist's perspective. J Community Hosp Intern Med Perspect (2017) 0.75
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer. Ann Surg (2008) 5.94
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut (2007) 4.51
Management of cirrhosis and ascites. N Engl J Med (2004) 4.31
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology (2003) 3.66
Role of a research ethics committee in follow-up and publication of results. Lancet (2003) 3.61
Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology (2003) 3.51
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology (2010) 3.45
A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology (2004) 3.42
A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol (2013) 3.41
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology (2007) 3.19
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology (2002) 2.93
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology (2008) 2.89
Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J (2009) 2.83
Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut (2011) 2.65
Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology (2012) 2.46
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol (2003) 2.37
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol (2003) 2.35
A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol (2008) 2.35
Management of patients with cirrhosis awaiting liver transplantation. Gut (2010) 2.34
Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology (2002) 2.34
Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology (2005) 2.29
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology (2010) 2.22
Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol (2012) 2.20
TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology (2002) 2.12
Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol (2013) 2.11
MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut (2007) 2.09
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology (2012) 2.03
[A secure job for ever]. Med Clin (Barc) (2003) 2.01
Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology (2003) 2.01
Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol (2009) 1.96
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology (2006) 1.96
Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology (2012) 1.92
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol (2003) 1.90
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol (2005) 1.87
Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol (2011) 1.87
Hepatorenal syndrome. Lancet (2003) 1.86
Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology (2006) 1.85
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol (2004) 1.82
Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J (2011) 1.79
A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology (2005) 1.77
Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology (2009) 1.76
Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology (2006) 1.71
Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl (2009) 1.69
The hepatic apelin system: a new therapeutic target for liver disease. Hepatology (2008) 1.67
Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology (2003) 1.66
Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology (2011) 1.65
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology (2003) 1.64
Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology (2006) 1.64